Cleveland BioLabs, Inc. 1 Company Profile
Cleveland BioLabs (CBL) was formed in June 2003. In September, 2003 CBL started its operations, supported by a R&D contract from the Cleveland Clinic Foundation (CCF). The company attracted a number of highly prestigious grants from NASA, NIH and DARPA. This funding support, along with investments from a number of angel investors, allowed CBL to build a strong research team and optimize its lead compounds. Clinical evaluation of these compounds will be supported by the round A investment closed in March 2005
Location
11000 Cedar Ave,
Cleveland
Ohio
44106
United States of America
Contact
Phone: 216-229-2251
Fax: 216-2291764
Email: info@cbiolabs.com
News Articles
Cleveland BioLabs planning follow-on
Cleveland BioLabs Inc. (NASDAQ:CBLI) said late Thursday it is planning a follow-on underwritten by Oppenheimer; Cantor Fitzgerald; and Ladenburg Thalmann. Cleveland BioLabs is developing CBLB502 for a...
Cleveland BioLabs adds $15 million
Cleveland BioLabs Inc. (NASDAQ:CBLI) raised $15 million through the sale of 7.5 million units at $2 in a follow-on underwritten by Oppenheimer; Cantor Fitzgerald; and Ladenburg Thalmann. Burrill was f...
Russia To Fund $4 Million Trials Of Cleveland BioLabs Stem Cell Booster
Russia’s Ministry of Industry and Trade reached a $4 million agreement with U.S.-based Cleveland BioLabs to form an alliance to develop a drug intended to stimulate the growth of stem cells.
Cleveland BioLabs rockets on survival data for radiation drug
Shares of Cleveland BioLabs skyrocketed as high as 89% on 4 June after the firm revealed strong survival results for its randomised, blinded, placebo-controlled efficacy study in non-human primates o...
Cleveland BioLabs and Russia team up on stem cell treatment
Cleveland BioLabs agreed to a $4 million deal with the Russian Ministry of Industry and Trade to develop CBLB612, a treatment -More-
BUFFALO, N.Y., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) announced today the online publication in the Journal of Immunology of a study demonstrating efficacy of Entolimod...
Oppenheimer startet Cleveland Biolabs mit outperform und Kursziel $3.
Oppenheimer startet Cleveland Biolabs mit outperform und Kursziel $3. (© BörseGo AG 2012 - Autor: Tobias Krieg, Redakteur)...
FDA grants orphan designation to Cleveland BioLabs cancer drug
Cleveland BioLabs' small-molecule curaxin CBL0102 obtained orphan-drug status from the FDA to treat hepatocellular carcinoma. -More-
Drugs and Medications
Ibuprofen [Genuine First Aid LLC]
Ibuprofen, 200 mg
Ke-53ps hand sanitizer [Kinzua Environmental Inc. ]
KE-53PS Gel Hand Sanitizer
Hygiene master instant hand sanitizer [Kayline Company]
Hygiene Master Instant Hand Sanitizer
Gfa 42 essential first aid items [Genuine First Aid LLC]
GFA 42 Essential First Aid Items
Arc 42 essential first aid items [American Red Cross]
ARC 42 Essential First Aid Items
PubMed Articles
The TONIC trial: A step forward in treating pediatric nonalcoholic fatty liver disease.
A 12-Year Perspective on the World's First Total Laryngeal Transplant.
Description of two new MICA alleles: MICA*058 and MICA*002:03.
We describe two novel alleles, MICA*058 and MICA* 002:03.
The 9-aminoacridine derivative quinacrine (QC) has a long history of safe human use as an anti-protozoal and anti-rheumatic agent. QC intercalates into DNA and RNA and can inhibit DNA replication, RNA...
Clinical Trials
The Comparability of Bispectral Index and Neurosense During Anesthesia
The assessment of anesthesia depth was based, until recently, on the evolution of hemodynamic parameters. Nowadays it can be evaluated by several monitoring methods, derived from electroen...
GeneBank at the Cleveland Clinic: Molecular Determinants of Coronary Artery Disease
This proposal delineates a research plan to collect blood from the patients undergoing heart catheterization or have had a heart catheterization within one year, coming in for outpatient a...
This is a randomized controlled trial of CMV-Ig in lung transplant recipients at the Cleveland Clinic Foundation who are hypogammaglobulinemic.
In this replication study at the Cleveland Clinic, we seek to collaborate to validate findings of the CardioGene Study in an independent cohort of patients who have undergone bare metallic...
Post-Op Quality of Life After Colorectal Surgery
The purpose of this study is to produce a user-friendly tool- in the form of a questionnaire - to accurately assess early quality of life in patients after abdominal colorectal surgery fro...
Companies
Cleveland BioLabs (CBL) was formed in June 2003. In September, 2003 CBL started its operations, supported by a R&D contract from the Cleveland Clinic Foundation (CCF). The company attracted a number o...
Chemokine.com is a product line from Torrey Pines Biolabs, Inc. established in San Diego, California, have been moved to Houston, Texas since January 2001. Torrey Pines Biolabs is an emerging biotechn...
Pacific BioLabs is an independent laboratory with over 25 years experience providing cGMP/GLP testing services to companies in the Pharmaceutical, Biopharm, Medical Device, Diagnostic and OECD/EPA reg...
Establish Delta Biolabs as the premier source of technically superior antibodies for the research community.In our endeavor to provide the highest quality reagents we will adhere to four values:100% C...
More Information about "Cleveland BioLabs, Inc. 1" on BioPortfolio
We have published hundreds of Cleveland BioLabs, Inc. 1 news stories on BioPortfolio along with dozens of Cleveland BioLabs, Inc. 1 Clinical Trials and PubMed Articles about Cleveland BioLabs, Inc. 1 for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cleveland BioLabs, Inc. 1 Companies in our database. You can also find out about relevant Cleveland BioLabs, Inc. 1 Drugs and Medications on this site too.
